<DOC>
	<DOCNO>NCT02798107</DOCNO>
	<brief_summary>Idarucizumab humanize monoclonal antibody fragment ( Fab ) bind dabigatran high affinity . Idarucizumab potently specifically bind dabigatran metabolite neutralises anticoagulant effect . A clinical development program ongoing support marketing authorisation submission idarucizumab indicated patient treat dabigatran require emergency surgery/urgent procedure life-threatening uncontrolledbleeding rapid reversal anticoagulant effect dabigatran require .</brief_summary>
	<brief_title>Observational Study Evaluate Safety Idarucizumab Pediatric Patients</brief_title>
	<detailed_description>Purpose : Study Design :</detailed_description>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<criteria>Inclusion criterion : Male female , &lt; 18 year age Were administer idarucizumab sit usage identify various method ( eg.through Idarucizumab drug administration surveillance program , spontaneous reporting ) Exclusion criterion : Participation dabigatran idarucizumab clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>